Mirae Asset Global Investments Co., Ltd. Inhibrx, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 01, 2024	BUY	$32.76 - $39.56 $46,715 - $56,412	1,426 Added 6.96%	21,920 $766,000
Q4 2023 Jan 24, 2024	BUY	$14.5 - $38.0 $19,299 - $50,578	1,331 Added 6.95%	20,494 $778,000
Q3 2023 Oct 26, 2023	SELL	$15.75 - $26.31 $11,891 - $19,864	-755 Reduced 3.79%	19,163 $351,000
Q2 2023 Aug 10, 2023	SELL	$16.96 - $27.82 $24,388 - $40,005	-1,438 Reduced 6.73%	19,918 $517,000
Q1 2023 May 04, 2023	BUY	$18.45 - $27.14 $124,150 - $182,625	6,729 Added 46.0%	21,356 $402,000
Q4 2022 Feb 09, 2023	BUY	$20.18 - $33.33 $41,954 - $69,293	2,079 Added 16.57%	14,627 $360,000
Q3 2022 Nov 10, 2022	BUY	$11.58 - $24.73 $145,305 - $310,312	12,548 New	12,548 $226,000

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $617M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.